Table 3.
OTCA Use in Past 30 Days
| Cirrhotic cases (n = 91) | Cirrhotic controls (n = 153) | Noncirrhotic controls (n = 89) | P | |
|---|---|---|---|---|
| Subjects using, n (%) | ||||
| OTCA | 32 (35) | 80 (52) | 62 (70) | <.001a |
| Acetaminophen | 17 (19) | 38 (25) | 37 (42) | .001b |
| NSAIDs | 15 (16) | 48 (31) | 30 (34) | .001c |
| Aspirin | 5 (6) | 12 (8) | 22 | |
| Ibuprofen | 5 (6) | 35 (23) | 9 | |
| Naproxen | 5 (6) | 4 (3) | 1 | |
| Days used, n (range) | .91 | |||
| Acetaminophen | 3 (1–30) | 3 (1–30) | 3 (1–30) | |
| NSAIDs | ||||
| Aspirin | 10 (1–30) | 1.5 (1–30) | 30 (10–30) | |
| Ibuprofen | 4 (1–21) | 3 (1–30) | 3 (1–15) | |
| Naproxen | 4 (1–15) | 1.5 (1–7) | 2 | |
| Amount used in 30 days, g (range) | .32 | |||
| Acetaminophen | 2.0 (0.3–39.0) | 2.3 (0.3–24.4) | 3.2 (0.3–39.0) | |
| NSAIDs | ||||
| Aspirin | 3.2 (0.62–9.75) | 1.3 (0.62–58.5) | 9.75 (1.22–39) | |
| Ibuprofen | 4.0 (0.5–31.5) | 2 (0.4–72) | 1.8 (0.4–22.5) | |
| Naproxen | 0.88 (0.22–6.6) | 0.36 (0.22–4.6) | 0.44 |
a
Differences significant among all groups.
b
Significant difference between noncirrhotic controls and the other 2 groups.
c
Significant difference between cirrhotic cases and both control groups.